The role of MRI in predicting Ki-67 in breast cancer: preliminary results from a prospective study

2018 ◽  
Vol 104 (6) ◽  
pp. 438-443 ◽  
Author(s):  
Corrado Caiazzo ◽  
Rosa Di Micco ◽  
Emanuela Esposito ◽  
Viviana Sollazzo ◽  
Maria Cervotti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Mri ◽  
Cancer Prognosis ◽  
Time Signal ◽  
Local Health ◽  
Ki 67 ◽  
Contrast Enhanced ◽  
Response To Chemotherapy ◽  
The Mean ◽  
The Relationship

Purpose: In the last decade contrast-enhanced magnetic resonance imaging (MRI) has gained a growing role as a complementary tool for breast cancer diagnosis. Currently the relationship between the kinetic features of a breast lesion and pathologic prognostic factors has become a popular field of research. Our aim is to verify whether breast MRI could be considered a useful tool to predict Ki-67 score, thus resulting as a breast cancer prognosis indicator. Methods: From June to December 2014, we enrolled patients with breast cancer who underwent preoperative dynamic contrast-enhanced MRI at the local health agency. We analyzed the time-signal intensity curves calculating the mean values of the following parameters: the basal enhancement (Ebase), the enhancement ratio (ENHratio), the maximum enhancement (Emax), and the steepest slope of the contrast enhancement curve (Smax). Scatterplots and Pearson correlation test were used to investigate the eventual associations among these parameters. Results: A total of 27 patients underwent breast MRI during the study period. The mean ± SD Ki-67 percentage was 27.03 ± 16.8; the mean Emax, Smax, Ebase, and ENHratio were 433.9 ± 120.2, 267.3 ± 96.8, 165.5 ± 77.1, and 187.1 ± 94.8, respectively. Scatterplots suggest a positive correlation between Ki-67 and both Emax and Smax. The correlation tests between Ki-67 and Emax, Ki-67 and Smax showed statistical significance. Conclusions: Our preliminary data suggest that enhancement pattern is closely linked to breast cancer proliferation, thus proving the relationship between more proliferating tumors and more rapidly enhanced lesions. This is hypothesis-generating for further studies aimed at promoting breast MRI in the early estimation of cancer prognosis and tumor in vivo response to chemotherapy.

The Pattern of Proline, Glutamic Acid, and Leucine-Rich Protein 1 Expression in Chinese Women with Primary Breast Cancer

2014 ◽  
Vol 29 (1) ◽  
pp. e1-e7 ◽  
Author(s):  
Yanzhi Zhang ◽  
Peng Wang ◽  
Mumu Shi ◽  
Hironobu Sasano ◽  
Monica S.M. Chan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamic Acid ◽  
Primary Breast Cancer ◽  
Chinese Women ◽  
Cancer Prognosis ◽  
Clinicopathological Parameters ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Her 2

Background Disparities of biomarkers’ expression in breast cancer across different races and ethnicities have been well documented. Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a novel ER coregulator, has been considered as a promising biomarker of breast cancer prognosis; however, the pattern of PELP1 expression in Chinese women with breast cancer has never been investigated. This study aims to provide useful reference on possible racial or ethnic differences of PELP1 expression in breast cancer by exploring the pattern of PELP1 expression in Chinese women with primary breast cancer. Methods The expression of PELP1 in primary breast cancer samples from 130 Chinese female patients was detected by immunohistochemistry and correlated to other clinicopathological parameters; for comparison, the expression of PELP1 in 26 benign breast fibroadenomas was also examined. Results The overall value of the PELP1 H-score in breast cancer was significantly higher than that in breast fibroadenoma (p<0.001). In our breast cancer patients, the ER/HER-2-positive group had significantly higher PELP1 H-scores than their negative counterparts (p=0.003 for ER and p=0.022 for HER-2); the Ki-67-high group also showed significantly higher PELP1 H-scores than the Ki-67-low group (p=0.008). No significant association between PELP1 H-scores and other clinicopathological parameters was found. Finally, the PELP1 H-score in breast cancers of the luminal B subtype was significantly higher than that in the triple negative subtype (p=0.002). Conclusion Overexpression of PELP1 in Chinese women with primary breast cancer appears to be associated with biomarkers of poor outcome; these results are similar to other reports based on Western populations.

Screening Breast MRI and Gadolinium Deposition: Cause for Concern?

2021 ◽  
Author(s):  
Colleen H Neal
Keyword(s):  
Breast Cancer ◽  
Renal Function ◽  
Contrast Agents ◽  
Biological Significance ◽  
Breast Mri ◽  
Reliable Data ◽  
Breast Cancer Data ◽  
Cancer Data ◽  
Contrast Enhanced ◽  
Gadolinium Retention

Abstract Gadolinium-based contrast agents (GBCAs) have been used worldwide for over 30 years and have enabled lifesaving diagnoses. Contrast-enhanced breast MRI is frequently used as supplemental screening for women with an elevated lifetime risk of breast cancer. Data have emerged that indicate a fractional amount of administered gadolinium is retained in the bone, skin, solid organs, and brain tissues of patients with normal renal function, although there are currently no reliable data regarding the clinical or biological significance of this retention. Linear GBCAs are associated with a higher risk of gadolinium retention than macrocyclic agents. Over the course of their lives, screened women may receive high cumulative doses of GBCA. Therefore, as breast MRI screening utilization increases, thoughtful use of GBCA is indicated in this patient population.

Characterization of Metastatic Sternal Lesions on Dynamic Contrast-Enhanced Breast MRI in Women with Invasive Breast Cancer

2019 ◽  
Vol 26 (10) ◽  
pp. 1358-1362
Author(s):  
Amie Y. Lee ◽  
Ryan Navarro ◽  
Lindsay P. Busby ◽  
Heather I. Greenwood ◽  
Matthew D. Bucknor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Breast Mri ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

scholarly journals BIRADS 4 breast lesions: comparison of contrast-enhanced spectral mammography and contrast-enhanced MRI

2019 ◽  
Vol 50 (1) ◽  
Author(s):  
Rabab Yasin ◽  
Enas Abd El Ghany
Keyword(s):  
Breast Cancer ◽  
Developing Countries ◽  
Statistical Significance ◽  
Breast Mri ◽  
Excision Biopsy ◽  
Breast Lesions ◽  
Common Cancer ◽  
Contrast Enhanced ◽  
Histopathological Result ◽  
Contrast Enhanced Mri

Abstract Background Breast cancer is the most common cancer in women worldwide. It is responsible for about 23% of cancer in females in both developed and developing countries [1]. We aimed to assess the accuracy of contrast-enhanced spectral mammography (CESM) versus contrast-enhanced breast MRI in the evaluation of BIRADS 4 breast lesions. Results Fifty patients were included in this study; there were 28 malignant cases and 22 benign cases; all cases were proved by histopathological result either by core biopsy or excision biopsy. CESM was found to have less sensitivity (94.1%) than MRI (100%) but CESM has higher specificity (100%) than MRI (95.5%). The accuracy of CESM was 96.4%, while the accuracy of MRI was 98.2% with no statistical significance (P value 0.827). Conclusion CESM can be used as a sensitive diagnostic tool in the detection and staging of breast cancer with higher specificity and less sensitivity as compared to contrast enhanced breast MRI.

scholarly journals Changes in Tumor Stem Cell Markers and Epithelial-Mesenchymal Transition Markers in Nonluminal Breast Cancer after Neoadjuvant Chemotherapy and Their Correlation with Contrast-Enhanced Ultrasound

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Xiaoling Leng ◽  
Guofu Huang ◽  
Lianhua Zhang ◽  
Jianbing Ding ◽  
Fucheng Ma
Keyword(s):  
Breast Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Two Dimensional ◽  
Intensity Curve ◽  
Time Intensity Curve ◽  
Mesenchymal Transition ◽  
Contrast Enhanced ◽  
Response To Chemotherapy ◽  
Perfusion Defects ◽  
Emt Markers

Nonluminal breast cancer has high early metastasis and treatment resistance, and neoadjuvant chemotherapy (NAC) is needed. The presence of cancer stem cells (CSC) and epithelial-mesenchymal transition (EMT) leads to poor prognosis. This study investigated the changes in CSC markers and EMT markers after NAC in nonluminal breast cancer and their correlation with contrast-enhanced ultrasound (CEUS) features and chemotherapy efficacy. Before NAC, the range of nonluminal breast cancer on CEUS was larger than that of two-dimensional ultrasound, but after NAC, it was significantly smaller than that of two-dimensional ultrasound and closer to the postoperative pathological size. After NAC, the enlarged lesions and perfusion defects were significantly less than those before NAC. The time-intensity curve showed the characteristics of slow-in, low enhancement, and low perfusion. Nonluminal breast cancer downregulated the expression of CSC markers and EMT markers after NAC, but the epithelial phenotype of nonluminal breast cancer with good response to chemotherapy was upregulated. In nonluminal breast cancer with poor response to chemotherapy, markers of CSC and EMT were highly expressed before chemotherapy. In conclusion, CEUS is better than conventional ultrasound in estimating NAC efficacy in this mode. CEUS can also predict the prognosis of nonluminal breast cancer before NAC with the characteristics of enhanced enlargement and perfusion defects. The contrast-enhanced time-intensity curve of lesions with relatively poor blood supply may have more CSC and EMT characteristics.

Rate of depressive episode in Peruvian oncologic outpatients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e12043-e12043
Author(s):  
Luis Furuya ◽  
Erick Infanzon ◽  
Diego Venegas
Keyword(s):  
Breast Cancer ◽  
Depressive Episode ◽  
Financial Status ◽  
The Poor ◽  
Epidemiological Features ◽  
Two Factors ◽  
Icd 10 ◽  
The Mean ◽  
The Relationship ◽  
Transversal Study

e12043 Background: Depression in Lima, Peru has a prevalence rate of 6.7% and lifetime prevalence of 19%. The relationship between depression and cancer has been widely studied, affects approximately 15% to 25% of cancer patients. However, there is little research in latin population. We report the results of evaluate the frequency of depressive disorder in Peruvian oncologic outpatients and describe clinical and epidemiological features Methods: A descriptive transversal study was performed to 70 patients that attended to oncology clinic at the Hospital Nacional Cayetano Heredia. Data was collected through a survey that included a clinical demographic record and the spanish version – ICD 10 of the Mini International Neuropsychiatric Interview for the diagnosis of depressive episode. Results: The 52% of the participants were females. The mean age was 57 years (18- 83 y) Breast cancer (21%) and lymphoma non Hodgkin (21%) were the most common types of cancer. The mean period from diagnosis was 5 month. The frequency of depressive episode was 21.4%. The 33.3% of women with breast cancer had depression, while patients with NHL had only 13.3% of frequency. We founded two factors with statistically significant association: poor financial status (p =0.041) and advance clinical stages (III and IV) (p = 0.026; OR: 6.8) Conclusions: The frequency of depressive episode was similar to other reports in the literature, the poor financial status and advanced stage are most associated with depression in our population

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: A meta-analysis.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21606-e21606
Author(s):  
Binliang Liu ◽  
Zongbi Yi ◽  
Xiuwen Guan ◽  
Fei Ma ◽  
Yi-Xin Zeng
Keyword(s):  
Breast Cancer ◽  
Protective Effect ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
All Cause Mortality ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
The Relationship ◽  
Statin Use

e21606 Background:Breast cancer is the most common cancer in females. The effects of statins on breast cancer prognosis have long been controversial, so it is important to investigate the relationship between statin type, exposure time, and breast cancer prognosis. This study sought to explore the effect of statins on breast cancer prognosis. Methods:We searched the MEDLINE, EMBASE, Cochrane Library between October 15, 2016 and January 20, 2017. Searches combined the terms “breast neoplasms[MeSH]”, “statins”, “prognosis” or “survival” or “mortality” with no limit on publication date. Data were analyzed using Stata/SE 11.0. Results: 7 studies finally met the selection criteria and 197,048 included women. Overall statin use was associated with lower cancer-specific mortality and all-cause mortality (HR 0.73, 95% CI 0.59-0.92, P = 0.000 and HR 0.72, 95% CI 0.58-0.89, P = 0.000). Lipophilic statins were associated with decreased breast cancer-specific and all-cause mortality (HR 0.57, 95% CI 0.46-0.70, P = 0.000 and HR 0.57, 95% CI 0.48-0.69, P = 0.000); however, hydrophilic statins were weakly protective against only all-cause mortality (HR 0.79, 95% CI 0.65-0.97, P = 0.132) and not breast cancer-specific mortality (HR 0.94, 95% CI 0.76-1.17, P = 0.174). Of note, more than four years of follow-up did not show a significant correlation between statin use and cancer-specific mortality or all-cause mortality (HR 0.84, 95% CI 0.71-1.00, P = 0.616 and HR 0.95, 95% CI 0.75-1.19, P = 0.181), while groups with less than four years of follow-up still showed the protective effect of statins against cancer-specific mortality and all-cause mortality (HR 0.62, 95% CI 0.44-0.87, P = 0.000 and HR 0.61, 95% CI 0.45-0.80, P = 0.000). Conclusions:Although statins can reduce breast cancer patient mortality, the benefit appears to be constrained by statin type and follow-up time. Lipophilic statins showed a strong protective function in breast cancer patients, while hydrophilic statins only slightly improved all-cause mortality. Finally, the protective effect of statins could only be observed in groups with less than four years of follow-up.

Magnetic Resonance Imaging of the Breast

2001 ◽  
Vol 8 (5) ◽  
pp. 399-406 ◽  
Author(s):  
Christopher P. Goscin ◽  
Claudia G. Berman ◽  
Robert A. Clark
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Clinical Studies ◽  
Breast Imaging ◽  
Breast Mri ◽  
Resonance Imaging ◽  
Valuable Adjunct ◽  
Interpretation Criteria ◽  
Contrast Enhanced

Background Magnetic resonance imaging (MRI) has the potential to become a useful adjunct in breast imaging. Contrast-enhanced breast MRI has demonstrated a high sensitivity in the detection of invasive breast cancer. In clinical studies, breast MRI has often altered the course of patient care. Although promising results have been generated, MRI of the breast is currently in a development stage. Methods The authors reviewed the literature on the potential indications, sensitivity, specificity, and limitations of MRI of the breast. Results Reported advantages of MRI of the breast over conventional imaging techniques include improved staging and treatment planning, enhanced evaluation of the augmented breast, better detection of recurrence, and improved screening of high-risk women. Contrast-enhanced breast MRI is a sensitive modality for detecting breast cancer, but its variable specificity is a major limitation. Conclusions MRI of the breast is emerging as a valuable adjunct to mammography and sonography for specific clinical indications. Additional clinical studies that define indications, interpretation criteria, imaging parameters, and cost effectiveness are needed. A multi-institutional study designed to address these issues is in progress.

Sign in / Sign up

Export Citation Format

Share Document